Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis)

Bauer, F.W.

doi:10.1016/s0190-9622(81)70025-2

Cited by 65 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…- Lichenoid eruptions have been reported with Qu, HCQ [69,70], CQ [71,72], Qud [73], and in soldiers who took Qn during World War II; they developed lichenoid eruption with rates between 1/2,000 on 100 mg daily to 1/500 on 200 mg daily, and some authors have suggested that such lichenoid reactions may precede Qn bone marrow toxicity [74]. …”

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

Background: Currently used antimalarial drugs (AM) are hydroxychloroquine and chloroquine, which are prescribed for many autoimmune disorders. The value of skin tests on cutaneous adverse drug reactions (CADR) with AM remains unknown. Objective: The main objective of this retrospective study is to know whether skin tests for AM are useful and how to manage the recovery of AM therapy in these patients. Methods: All patients referred for suspected CADR secondary to AM between 2001 and 2014 in eight French dermatology centers were retrospectively reviewed. Results: We report herein a retrospective series of 20 patients with CADR and AM involvement. Skin tests, performed in 14/20 patients, were negative in all cases. Six patients had an oral provocation test with recurrence of CADR in 1 case. Conclusion: We encourage dermatologists to perform oral provocation tests in nonsevere CADR in order to allow AM rechallenge at progressive doses.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

show abstract

“…4 Experience with quinacrine used for malaria prophylaxis in the second world war shows that lichenoid skin eruptions were the most common adverse effect of this drug. 3 However, it should be remembered that higher daily doses of quinacrine (300-400 mg/day) were commonly used than compared to today (100 mg/day). 15 Induction or exacerbation of cutaneous LE by antimalarials has been reported informally but not well documented.…”

Section: Discussionmentioning

confidence: 99%

“…The ability of antimalarials to induce lichenoid reactions has been well documented. 3,4 However, the induction of cutaneous LE or the exacerbation of pre-existing cutaneous LE by antimalarials has been less well described and can result in a particularly confusing scenario for the clinician. The histology of drug induced cutaneous LE is commonly indistinguishable from idiopathic cutaneous LE.…”

Section: Introductionmentioning

confidence: 99%

Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus

Geraminejad

Stone

Sontheimer

2004

Lupus

View full text Add to dashboard Cite

Recently a number of cases of drug induction or exacerbation of lupus erythematosus (LE) specific skin disease have been described in the literature. Many of the responsible medications are also known for their ability to induce a lichenoid tissue reaction. Aminoquinoline antimalarials are currently the first line of therapy in cutaneous LE specific skin disease. Lichenoid tissue reactions are among the most common cutaneous side effects of aminoquinolone antimalarials. We report three cases of aminoquinolone antimalarial induced or exacerbated LE specific skin disease. We also review the pathophysiology of LE specific skin disease and propose a mechanism by which induction of the lichenoid tissue reaction may result in Koebnerization of LE specific skin lesions.

show abstract

“…Eighty percent were eczematous and twenty percent were lichenoid or exfoliative [67]. Lichen planus was observed in 1 of 2,000 soldiers given 100 mg/day and in 1 of 500 given 200 mg/day.…”

Section: Dermatologic Toxicitymentioning

confidence: 99%

“…The dermatitis quickly resolved upon cessation of drug administration. Quinacrine can produce a yellow stain in the skin as well as areas of discoloration appearing like "black and blue marks" or bruises presumably due to melanin binding [67-69]. Slate-colored pigmentation of the palate and subungual areas were described in soldiers treated with quinacrine hydrochloride by Lippard and Kauer [69].…”

Section: Dermatologic Toxicitymentioning

confidence: 99%

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

2011

View full text Add to dashboard Cite

This is an in-depth review of the history of quinacrine as well as its pharmacokinetic properties and established record of safety as an FDA-approved drug. The potential uses of quinacrine as an anti-cancer agent are discussed with particular attention to its actions on nuclear proteins, the arachidonic acid pathway, and multi-drug resistance, as well as its actions on signaling proteins in the cytoplasm. In particular, quinacrine's role on the NF-κB, p53, and AKT pathways are summarized.

show abstract

Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis)

Cited by 65 publications

References 15 publications

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

Contact Info

Product

Resources

About